Home
/
AGIOS PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
AGIOS PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that AGIOS PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2018
Jun 30, 2018
$40.41M
Aug 2, 2018
Q1
2018
Mar 31, 2018
$8.76M
May 4, 2018
Q3
2017
Sep 30, 2017
$11.36M
Nov 1, 2017
Q2
2018
Jun 30, 2017
$11.35M
Aug 2, 2018
Q1
2018
Mar 31, 2017
$10.51M
May 4, 2018
Q3
2017
Sep 30, 2016
$8.99M
Nov 1, 2017
Q2
2017
Jun 30, 2016
$6.98M
Aug 8, 2017
Q2
2014
Jun 30, 2014
$8.40M
Aug 7, 2014
Q1
2014
Mar 31, 2014
$8.40M
May 9, 2014
Q3
2013
Sep 30, 2013
$6.27M
Nov 7, 2013
Q2
2014
Jun 30, 2013
$6.30M
Aug 7, 2014
Q1
2014
Mar 31, 2013
$6.30M
May 9, 2014
Q3
2013
Sep 30, 2012
$6.27M
Nov 7, 2013
Q2
2013
Jun 30, 2012
$6.29M
Sep 5, 2013
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$12.88M
Oct 30, 2025
Q2
2025
Jun 30, 2025
$12.46M
Jul 31, 2025
Q1
2025
Mar 31, 2025
$8.73M
May 1, 2025
Q3
2025
Sep 30, 2024
$8.96M
Oct 30, 2025
Q2
2025
Jun 30, 2024
$8.62M
Jul 31, 2025
Q1
2025
Mar 31, 2024
$8.19M
May 1, 2025
Q3
2024
Sep 30, 2023
$7.40M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$6.71M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$5.61M
May 2, 2024
Q3
2023
Sep 30, 2022
$3.52M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$5.58M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$832.0K
May 4, 2023
Q3
2022
Sep 30, 2021
$0
Nov 3, 2022
Q2
2022
Jun 30, 2021
$0
Aug 4, 2022
Q1
2022
Mar 31, 2021
$0
May 5, 2022
Q3
2020
Sep 30, 2020
$34.71M
Nov 5, 2020
Q2
2020
Jun 30, 2020
$37.35M
Jul 30, 2020
Q1
2020
Mar 31, 2020
$87.10M
Apr 30, 2020
Q3
2020
Sep 30, 2019
$26.02M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$26.22M
Jul 30, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($103.43M)
Oct 30, 2025
Q3
2025
Jun 30, 2025
($112.02M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($112.02M)
Jul 31, 2025
Q1
2025
Mar 31, 2025
($89.29M)
May 1, 2025
Q3
2025
Mar 31, 2025
($89.29M)
Oct 30, 2025
Q2
2025
Mar 31, 2025
($89.29M)
Jul 31, 2025
Q3
2025
Sep 30, 2024
$947.92M
Oct 30, 2025
Q2
2025
Jun 30, 2024
($96.12M)
Jul 31, 2025
Q3
2025
Jun 30, 2024
($96.12M)
Oct 30, 2025
Q1
2025
Mar 31, 2024
($81.55M)
May 1, 2025
Q2
2025
Mar 31, 2024
($81.55M)
Jul 31, 2025
Q3
2025
Mar 31, 2024
($81.55M)
Oct 30, 2025
Q3
2024
Sep 30, 2023
($91.32M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($83.81M)
Aug 1, 2024
Q3
2024
Jun 30, 2023
($83.81M)
Oct 31, 2024
Q2
2024
Mar 31, 2023
($81.02M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($81.02M)
May 2, 2024
Q3
2024
Mar 31, 2023
($81.02M)
Oct 31, 2024
Q3
2023
Sep 30, 2022
($81.75M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($91.81M)
Aug 3, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($116.87M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($127.06M)
Jul 31, 2025
Q1
2025
Mar 31, 2025
($106.63M)
May 1, 2025
Q3
2025
Sep 30, 2024
($102.81M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($105.82M)
Jul 31, 2025
Q1
2025
Mar 31, 2024
($92.07M)
May 1, 2025
Q3
2024
Sep 30, 2023
($100.90M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($93.70M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($90.61M)
May 2, 2024
Q3
2023
Sep 30, 2022
($91.09M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($97.64M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($101.15M)
May 4, 2023
Q3
2022
Sep 30, 2021
($91.15M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($91.22M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($91.22M)
May 5, 2022
Q3
2021
Sep 30, 2020
($80.29M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($83.26M)
Jul 29, 2021
Q1
2021
Mar 31, 2020
($87.03M)
Apr 29, 2021
Q3
2020
Sep 30, 2019
($109.06M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($113.86M)
Jul 30, 2020